Cargando…

Dendritic Cell-Based Immunotherapy for Prostate Cancer

Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conduct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jähnisch, Hanka, Füssel, Susanne, Kiessling, Andrea, Wehner, Rebekka, Zastrow, Stefan, Bachmann, Michael, Rieber, Ernst Peter, Wirth, Manfred P., Schmitz, Marc
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2975068/ https://www.ncbi.nlm.nih.gov/pubmed/21076523 http://dx.doi.org/10.1155/2010/517493

Ejemplares similares

Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer
por: Kiessling, Andrea, et al.
Publicado: (2012)

Identification of an HLA-A(*)0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein
por: Kiessling, A, et al.
Publicado: (2004)

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy
por: Schmitz, M, et al.
Publicado: (2007)

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy
por: Schmitz, M, et al.
Publicado: (2007)

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010)

A Novel Modular Antigen Delivery System for Immuno Targeting of Human 6-sulfo LacNAc-Positive Blood Dendritic Cells (SlanDCs)
por: Bippes, Claudia C., et al.
Publicado: (2011)

Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100
por: Naumann, Kai, et al.
Publicado: (2013)

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
por: Tunger, Antje, et al.
Publicado: (2018)

Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma
por: Plesca, Ioana, et al.
Publicado: (2022)

Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis
por: Thomas, Katja, et al.
Publicado: (2014)

Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer
por: Kießler, Maximilian, et al.
Publicado: (2021)

Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
por: Plesca, Ioana, et al.
Publicado: (2020)

Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets
por: Müller, Luise, et al.
Publicado: (2020)

Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma
por: Weber, Thomas, et al.
Publicado: (2014)

NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
por: Murad, Shafiq, et al.
Publicado: (2022)

Lack of Ephrin Receptor A1 Is a Favorable Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
por: Toma, Marieta I., et al.
Publicado: (2014)

Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma
por: Dornbusch, Juana, et al.
Publicado: (2013)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer
por: Al-Janabi, Omar, et al.
Publicado: (2014)

Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc(+) Monocytes in Rectal Cancer
por: Wagner, Felix, et al.
Publicado: (2019)

Dendritic Cells and Their Role in Immunotherapy
por: Gardner, Alycia, et al.
Publicado: (2020)

Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer
por: Schimmelpfennig, Carolin, et al.
Publicado: (2023)

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
por: Mu, L J, et al.
Publicado: (2005)

A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
por: Büttner, Florian A., et al.
Publicado: (2022)

Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy
por: Froehner, Michael, et al.
Publicado: (2018)

Dendritic cell immunotherapy: clinical outcomes
por: Apostolopoulos, Vasso, et al.
Publicado: (2014)

Tolerogenic dendritic cell-based immunotherapy
por: Chang, Kiyuk, et al.
Publicado: (2017)

Plasmacytoid Dendritic Cells and Cancer Immunotherapy
por: Fu, Chunmei, et al.
Publicado: (2022)

Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy
por: Aldahlawi, Alia M., et al.
Publicado: (2021)

CD8(+) T Cells Mediate CD40-independent Maturation of Dendritic Cells In Vivo
por: Ruedl, Christiane, et al.
Publicado: (1999)

Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?
por: Thomas, Christian, et al.
Publicado: (2021)

Gamma irradiation preserves immunosuppressive potential and inhibits clonogenic capacity of human bone marrow-derived mesenchymal stromal cells
por: de Andrade, Ana Valéria Gouveia, et al.
Publicado: (2014)

Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis
por: Fuessel, Susanne, et al.
Publicado: (2014)

Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation
por: Erdmann, Kati, et al.
Publicado: (2017)

Dendritic Cell Based PSMA Immunotherapy for Prostate Cancer Using a CD40-Targeted Adenovirus Vector
por: Williams, Briana Jill, et al.
Publicado: (2012)

Dendritic Cell-Based Immunotherapy for Myeloid Leukemias
por: Schürch, Christian M., et al.
Publicado: (2013)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

Regulatory Dendritic Cells for Immunotherapy in Immunologic Diseases
por: Gordon, John R., et al.
Publicado: (2014)

Dendritic Cell-Based Immunotherapy for Solid Tumors()()
por: Jung, Nam-Chul, et al.
Publicado: (2018)

Manufacturing Dendritic Cells for Immunotherapy: Monocyte Enrichment
por: Hopewell, Emily L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_emj4i78pb4vbm04cr9uoapr6us